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Advanced Review
Mitochondrial metabolic
remodeling in response to genetic
and environmental perturbations
Kate E.R. Hollinshead and Daniel A. Tennant*
Mitochondria are metabolic hubs within mammalian cells and demonstrate sig-
niﬁcant metabolic plasticity. In oxygenated environments with ample carbohy-
drate, amino acid, and lipid sources, they are able to use the tricarboxylic acid
cycle for the production of anabolic metabolites and ATP. However, in conditions
where oxygen becomes limiting for oxidative phosphorylation, they can rapidly
signal to increase cytosolic glycolytic ATP production, while awaiting hypoxia-
induced changes in the proteome mediated by the activity of transcription factors
such as hypoxia-inducible factor 1. Hypoxia is a well-described phenotype of
most cancers, driving many aspects of malignancy. Improving our understanding
of how mitochondria change their metabolism in response to this stimulus may
therefore elicit the design of new selective therapies. Many of the recent
advances in our understanding of mitochondrial metabolic plasticity have
been acquired through investigations of cancer-associated mutations in meta-
bolic enzymes, including succinate dehydrogenase, fumarate hydratase, and iso-
citrate dehydrogenase. This review will describe how metabolic perturbations
induced by hypoxia and mutations in these enzymes have informed our knowl-
edge in the control of mitochondrial metabolism, and will examine what this
may mean for the biology of the cancers in which these mutations are observed.
© 2016 The Authors. WIREs Systems Biology and Medicine published by Wiley Periodicals, Inc.
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INTRODUCTION
Mitochondria are a ubiquitous feature of eukary-otic cells, thought to have been incorporated
as a core component of our cellular machinery at
approximately the same time as the increase in
atmospheric oxygen levels, around 1.5 billion years
ago.1 They are hypothesized to be the foundation of
many aspects of metazoan phenotype, including the
ability to differentiate and our considerable meta-
bolic plasticity. Mitochondria are also unique within
the eukaryotic cell, consisting of a double lipid
bilayer, a speciﬁc lipid component (cardiolipin) not
otherwise found in the cell, and their own DNA. As
metabolic hubs of the cell, mitochondria integrate the
use of diverse carbon sources, including sugars and
their downstream metabolites, lipids, amino acids,
and ketone bodies for the generation of cellular
energy (ATP). They are also central to the conversion
of one carbon source into another, permitting the
synthesis of lipids from sugars and glucose from
amino acids. Without them, cells would be forced to
rely on exogenous nutrient sources for processes such
as cell repair and proliferation.
The function of mammalian mitochondria is
greatly dependent on an oxygenated microenviron-
ment and a highly regulated complement of meta-
bolic enzymes, some of which are unique within the
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cell. In the early 1900s, Dr Otto Warburg made the
observation that cancer cells produce signiﬁcant lac-
tate in the presence of oxygen, which led him to
the assertion that mitochondrial dysfunction was a
root cause of all cancers.2,3 Although this was later
shown not to be the case as a generalized mechan-
ism, it has not escaped the attention of cancer biol-
ogists more recently that mitochondrial dysfunction
is often observed in cancer.4–6 However, the role of
this dysfunction—whether a driver, a necessary sup-
porter, or just a side act—is not always clear. This
review will outline from a cancer perspective how
mitochondrial function is known to be affected by
oxygen tension, and the effect of mutations in some
of the metabolic enzymes within and associated
with the mitochondria that have been shown to
play a role in the formation or phenotype of some
cancers.
HYPOXIA AND MITOCHONDRIAL
FUNCTION
As tumors grow from a single transformed cell into a
cell mass, they create a signiﬁcant demand for glu-
cose and oxygen that outweighs supply. The partial
pressure of oxygen therefore decreases within the
tumor, resulting in a reduced ability of cells to pro-
duce ATP through oxidative phosphorylation. In
turn, the repression of respiration on glycolysis is
lost, and glycolytic ATP production increases to com-
pensate.7 Decreased respiration also results in a
reduction in the rate of NADH oxidation by complex
I of the respiratory chain, leading to an increase in
the NADH:NAD+ ratio in the mitochondria.8,9
This increase inhibits the reducing potential of the
cytosolic NADH produced in glycolysis from being
transferred into the mitochondria through the
malate–aspartate shuttle. As a result, the NADH
must be oxidized in the cytosol to permit continued
ATP production through glycolysis by the reduction
of pyruvate to lactate. Without any compensatory
steps, the increase in the NADH:NAD+ ratio in the
mitochondria means that in hypoxia, the NADH-
producing reactions of the tricarboxylic acid (TCA)
cycle are inhibited (Figure 1), reducing ﬂux through
the pathway, and thereby inhibiting oxidative ana-
bolic metabolism from mitochondrial carbon sources.
As a result, cells would be forced into a nonprolifera-
tive, energy-sparing phenotype—producing most
ATP through glycolysis and downregulating pro-
cesses that demand signiﬁcant energy and macromo-
lecules such as protein synthesis. Hypoxia has
previously been shown to elicit an autophagic
response,8,10 which could supply some cellular
macromolecules, but without a degree of mitochon-
drial remodeling, continued anabolism in these con-
ditions is not possible.8 Instead, as a measure of
compensation, the TCA cycle is split into a number
of linear pathways under these conditions.
In diving mammals and marine invertebrates,
which can survive underwater for signiﬁcant peri-
ods, it has been noted that succinate accumulates in
the peripheral blood while the animal is in hypoxic
conditions.11 Indeed, the hypoxic accumulation of
succinate has been observed in mammalian tissues,
and has been attributed to the mitochondrial reduc-
tion of fumarate by succinate dehydrogenase (SDH)
to continue NADH oxidation by complex I12,13—a
functional reversibility that has been known for over
50 years.14 This means that mitochondrial ATP syn-
thesis as well as glycolysis can be maintained with
reduced lactate production, and therefore with a
longer period before acidosis, decreasing the need to
resurface to service the oxygen debt. The fumarate
reductase activity of SDH has now been described in
both normal ischemic and hypoxic cancer cells,
showing that this is a universal phenotype of mam-
malian mitochondria.13,15 In these conditions, a
source of mitochondrial fumarate is required. It has
been suggested in ischemic cells that both import of
aspartate and reversal of part of the TCA cycle and
the use of the purine nucleotide cycle can provide
sources of fumarate.13 The purine nucleotide cycle is
an extra-mitochondrial cycle that is required to ami-
nate inosine monophosphate (IMP) to form adeno-
sine monophosphate through the activities of
adenylosuccinate synthetase (ADSS) and adenylosuc-
cinate lyase (ADSL). The amine group is provided
by aspartate, which as a result is converted to fuma-
rate (Figure 1), and the AMP can be used in energy
metabolism or to complete the cycle through the
activity of AMP deaminase (AMPD), which evolves
ammonium and IMP.
The metabolism of hypoxic mitochondria in a
cellular context has also been shown to produce
higher levels of reactive oxygen species (ROS) than in
normoxia.16 Reduced complex I and III have been
shown to donate electrons to available oxygen, form-
ing the highly reactive superoxide radical, which can
oxidize available proteins, lipids, and DNA in the
nearest vicinity or be dismuted to hydrogen peroxide,
which is able to travel further and oxidize molecules
in more of the cellular space.9 There are a number of
mitochondrial enzymes that are highly susceptible to
oxidant-mediated inactivation, including complex I,
aconitase, and α-ketoglutarate dehydrogenase
(αKGDH).17–20 Interestingly, the inactivation of
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aconitase and αKGDH has signiﬁcantly different
effects on mitochondrial metabolic activity. Inactiva-
tion of the former results in a loss of citrate oxidation
in the TCA cycle but permits the continuation of glu-
tamine oxidation, whereas inactivation of the latter
would inhibit any glutamine oxidation, but could
permit other NADH-producing reactions to continue
(Figure 1). Inactivation of either enzyme therefore
forms linear metabolic pathways from the TCA cycle
enzymes in hypoxia.
In addition to the direct effects of hypoxia on
mitochondrial metabolism, there are also indirect
effects as a result of transcriptional changes induced
by low oxygen. The initial growth of a cancer results
in areas of low oxygen tension found throughout the
tumor mass, away from the functional blood vessels.
This results in the inhibition of the oxygen-mediated
repression of a small family of heterodimeric tran-
scription factors known as hypoxia-inducible factors
(HIFs). These transcription factors can then move to
the nucleus where they bind the p300/CBP [cyclic
AMP-responsive element-binding (CREB) protein]
histone acetyl transferases to decondense chromatin
and transcribe their target genes.21 The oxygen sen-
sors for this process are a family of three prolyl
hydroxylase enzymes known as the PHDs. These
enzymes form part of a larger superfamily of non-
heme iron α-ketoglutarate (αKG)-dependent dioxy-
genases found in multiple phyla, and use oxygen and
αKG to hydroxylate a peptidyl prolyl residue in their
target proteins, resulting in the formation of succi-
nate and CO2.
22 The hydroxylation of HIFα subunits
causes them to be recognized and bound by the E3
ubiquitin ligase, von Hippel Lindau protein (pVHL),
polyubiquitylated, and subsequently degraded by the
proteasome.23,24 The exquisite sensitivity of this
process means that the half-life of HIF1α is thought
to be the shortest known of any protein.
Since its discovery, HIF1 has been shown to
regulate a number of transcripts that can directly and
indirectly modulate mitochondrial metabolism.
Indeed, HIF1 expression in hypoxia has been shown
to be central for continued viability.25 Perhaps the
best described mitochondrial metabolic HIF1 target
gene is pyruvate dehydrogenase kinase 1
(PDK1).25,26 The kinase encoded by this gene alters
FIGURE 1 | Hypoxia-induced changes in mitochondrial metabolism. Changes that have been described to occur in human mitochondria under
hypoxia are shown on a background of normoxic metabolism. Hypoxia-induced changes in pathway use are shown as thicker lines, while the
reversal of succinate dehydrogenase (SDH) activity is shown as a blue line. Metabolic enzymes are shown in red. Abbreviations: AcCoA, acetyl
CoA; ACO1, cytosolic aconitase; ACO2, mitochondrial aconitase; ADSS, adenylosuccinate synthetase; ADSL, adenylosuccinate lyase; a-KG,
α-ketoglutarate; a-KGDH, α-ketoglutarate dehydrogenase; Asp, aspartate; Cit, citrate; FAD+, ﬂavin adenine dinucleotide; FADH2, reduced ﬂavin
adenine dinucleotide; Fum, fumarate; Glc, glucose; Gln, glutamine; Glu, glutamate; IDH1, cytosolic isocitrate dehydrogenase; IDH2, mitochondrial
isocitrate dehydrogenase; Lac, lactate; LDH, lactate dehydrogenase; Mal, malate; NAD+, nicotinamide adenine dinucleotide; NADH, reduced
nicotinamide adenine dinucleotide; OAA, oxaloacetate; PC, pyruvate carboxylase; PDH, pyruvate dehydrogenase; PDK1, pyruvate dehydrogenase
kinase 1; Pyr, pyruvate; ROS, reactive oxygen species; Suc, succinate.
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mitochondrial metabolism through the phosphoryla-
tion and inhibition of the E1α subunit of the pyru-
vate dehydrogenase complex (PDC), which
oxidatively decarboxylates pyruvate to form acetyl
CoA, a very important donor of mitochondrial acetyl
groups to not only the epigenetic machinery but also
the TCA cycle. The upregulation of PDK1 and conse-
quent inhibition of the PDC has been shown as vital
in maintaining cell viability in hypoxia, through the
reduction of ROS production and stabilization of
ATP levels.25 These phenotypes could be designed to
avoid activation of cellular senescence pathways in
hypoxia, as suppression of the PDC by oncogene
activation has recently been shown as critical in sup-
pressing oncogene-induced senescence (OIS).27
Indeed, further evidence of the use of metabolic
remodeling in hypoxia to avoid ROS-mediated senes-
cence arises from evidence that inhibition of the
increased glycogen metabolism observed in hypoxia
results in senescence through increased ROS produc-
tion.28 It is therefore likely that the inhibition of the
PDC by HIF1-induced PDK1 upregulation reduces
ROS-induced senescence in hypoxia. However, loss
of pyruvate oxidation can also result in a truncated
TCA cycle, in which the oxaloacetate (OAA) pro-
duced by glutamine oxidation cannot be used to pro-
duce citrate without another source of mitochondrial
acetyl CoA. It is possible that the pool of acetyl CoA
is maintained through the β oxidation of fatty acids
in hypoxia, but if the mitochondrial aconitase is also
inhibited in these conditions, through the increased
production of ROS in hypoxia, this is unlikely.
Loss of PDC activity has been shown to result
in a change in the citrate to αKG ratio in the cell,
which has been suggested to be a prerequisite for a
change in the way in which glutamine is metabolized:
inducing an increase in the use of reductive carboxyl-
ation of this amino acid29 (Figure 1). This is a poten-
tially important pathway in hypoxia, as pyruvate
oxidation is inhibited by HIF1-dependent upregula-
tion of PDK1, producing a deﬁcit of the metabolites
in the proximal portion of the TCA cycle (citrate and
isocitrate). Indeed, as previously suggested, a reduc-
tion in oxygen tension may also be limiting for oxi-
dation of glutamine, making reductive carboxylation
more relied upon for anabolic metabolism.30 The
enzymes responsible for the reductive metabolism of
glutamine can be found both in the mitochondrial
matrix and the cytosol (ACO2 and IDH2; ACO1
and IDH1, respectively), and may be able to compen-
sate for this deﬁcit in these conditions.29,31 It is there-
fore consistent that reductive carboxylation has been
suggested as an essential pathway for cancer cell
survival in hypoxia or for those with defective oxida-
tive mitochondrial machinery.30,32–34 Although it is
theoretically possible that both pathways contribute
to this reductive activity, the cytosolic compartment
is much more easily accessible to exogenous gluta-
mine than the mitochondrial matrix, as the latter
requires transport of the precursor (glutamine/gluta-
mate/αKG) into the matrix and the transport of the
resulting citrate out. It is unknown how hypoxia may
alter the activity of the necessary transporters, which
requires further study.
Further HIF1-dependent modiﬁcation of mito-
chondrial metabolism in hypoxia has been reported
through subunit switching of complex IV (cyto-
chrome c oxidase, COX) of the respiratory chain.
COX is a homodimer with 13 subunits per mono-
mer, which sits within the mitochondrial inner mem-
brane.35 In common with most complexes of the
respiratory chain, the subunits of COX are encoded
by genes in both the mitochondrial and nuclear
DNA. COX4, one of the centrally situated subunits
of the complex, is encoded by the nuclear genome
with two paralogues: COX4-1 and COX4-2.36 In
both yeast (in which this subunit is known as Cox5)
and some human tissues, reduction in environmental
oxygen tension elicits a repression of the expression
of the ‘a’ or ‘1’ subunit and an increase in expression
of the ‘b’ or ‘2’ subunit.37–39 In cancer cells, it was
shown that this switching was brought about by the
HIF1-induced expression of the COX4-2 transcript,
alongside increased expression of the mitochondrial
LON protease, which degraded the COX4-1 subu-
nit.37 From studies in yeast, it is thought that expres-
sion of the ‘b’ subunit may permit a more rapid
transfer of electrons to COX1 from the heme moi-
ety.40,41 The study by Fukuda et al. in cancer cells
suggests that this may reduce mitochondrial ROS
production in hypoxia.37 However, the general over-
all effect of this on hypoxic mitochondrial biology is
not entirely clear, as it appears that COX4-2 expres-
sion may only be regulated by hypoxia in a subset of
tissues (lung and liver).37
The major hydroxylase that determines HIF1α
stability is PHD2,42 suggesting that the majority of
HIF1-mediated changes in mitochondrial metabolism
are dependent on the inhibition of PHD2 in hypoxia.
However, recent studies investigating the PHD1−/−
mouse have shown that hypoxia may induce other
changes in mitochondrial metabolic activity, inde-
pendently of HIF1.43,44 These changes have not yet
been adequately studied and represent a signiﬁcant
gap in our knowledge of how hypoxia remodels cel-
lular metabolism in general.
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MUTATIONS OF MITOCHONDRIAL
(AND ASSOCIATED) METABOLIC
ENZYMES IN CANCER
The identiﬁcation of cancer-associated mutations in
the metabolic enzymes such as fumarate hydratase
(FH), SDH, and isocitrate dehydrogenase (IDH) has
demonstrated that altered mitochondrial metabolism
is sufﬁcient to transform some cell types.45 FH and
SDH are bone ﬁde tumor suppressor genes, inactivat-
ing mutations in which have been identiﬁed as causa-
tive in cancers such as renal clear-cell carcinoma and
paraganglioma.46–50 Mutations in IDH1 and IDH2
are common in a variety of diverse cancers, including
adult gliomas51,52 and acute myelogenous leukemia
(AML),53,54 but unlike FH and SDH, are genetic
oncogenes. A single hit, which is both loss of func-
tion and gain of function, is only ever observed in
these genes. In both gliomas and AML, mutations in
IDH genes have been suggested as a very early, and
perhaps founder mutations, although in neither dis-
ease does IDH mutation appear to be able to induce
transformation on its own.55–58 What is common to
all three genes is that they are either situated directly
within the mitochondrial matrix (SDH, FH, and
IDH2) or their metabolic activity directly affects that
of the mitochondrion (IDH1). In addition, the
cancer-associated mutations observed have all been
reported to interact with the HIF system; in the case
of FH and SDH mutations, these unequivocally result
in HIFα stabilization, whereas in the case of IDH1
and IDH2, it appears that mutation may destabilize
hypoxic HIFα stabilization. In the latter case, it
would appear that the biological outcome of this is
not yet clear. Mutations in these enzymes therefore
have a dual outcome on mitochondrial metabolic
activity: they both alter HIF1 activity and they
directly alter metabolism.
Succinate Dehydrogenase
SDH is a highly conserved heterotetrameric complex
encoded entirely by the nuclear genome. It is respon-
sible for the oxidation of succinate to fumarate in the
TCA cycle and the transfer of electrons to ubiqui-
none, transfer of which is required by complex III to
pump protons. Complex II itself is unique in the res-
piratory chain as the only complex without proton
pumping function. The complex consists of two sub-
units (SDHA and SDHB), which protrude into the
mitochondrial matrix, and two hydrophobic subunits
(SDHC and SDHD), which anchor the catalytic com-
ponents to the inner mitochondrial membrane and
produce the binding site for ubiquinone.59 Mutations
in SDHD were the ﬁrst to be identiﬁed as causative
in patients with hereditary paragangliomas and later
pheochromocytomas, rare neuroendocrine neoplasms
of the chromafﬁn tissue of the adrenal medulla and
the parasympathetic tissue of the head and neck
paraganglioma, respectively.50 Since the initial dis-
covery of SDHD mutations in 2000, mutations in
SDHB and SDHC, and more recently, SDHA and
SDHAF2 (encoding the protein responsible for FAD
incorporation into SDH) have been identiﬁed with
the same syndrome.47–49,60 These mutations are
found as heterozygous germline mutations, which
means that loss of protein function and neoplastic
transformation develops as a result of loss of hetero-
zygosity, resulting in the complete loss of enzyme
function by a second ‘hit.’61 Inactivating mutations
of SDH subunits have since been reportedly associ-
ated with other tumor types including gastrointesti-
nal stromal tumors,62 renal cell carcinoma,63,64 and
neuroblastoma.65,66 Interestingly, mutations of
SDHB predispose to a more malignant and aggressive
form of paraganglioma than those of the other subu-
nits, despite the apparent similarities in both func-
tional and downstream phenotypic consequences of
this mutation. It is apparent from this clinical per-
spective that we do not fully understand the role of
SDHB in SDH function.
SDH is one of the few enzymes in the TCA
cycle that are unique to the mitochondrion, making
this compartment the major source of succinate, and
the only one in which it can be further metabolized
within the mammalian cell. Loss of SDH function
through mutation in any one of the subunits results
in loss of dehydrogenase activity, succinate accumu-
lation within the cell, and excretion into the extracel-
lular space. The signiﬁcant increase in succinate
concentrations leads to the inhibition of all members
of the αKG-dependent dioxygenase family that have
been reported, including histone and DNA demethy-
lases and the PHDs. This produces a hypermethyla-
tor phenotype of the chromatin67 as well as a
pseudohypoxic phenotype through the stabilization
of HIF in the presence of oxygen.68 This has the sig-
niﬁcant consequence of changing mitochondrial
activity to a more ‘hypoxia-like’ state through HIF1
signaling. In addition, it has been suggested that
SDH-deﬁcient mitochondria may generate more
superoxide, resulting in additional enzyme inactiva-
tion as previously described for hypoxia.69
Although the loss of SDH activity within the
mitochondria produces another form of truncated
TCA cycle (Figure 2), the signiﬁcant production of
succinate shows that this new TCA cycle activity is
used by cells. However, until recently, the models
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available for interrogation of this activity were lack-
ing. Two recent studies have described aspects of the
metabolic remodeling that mitochondria undergo in
the absence of Sdhb.70,71 As would be expected from
the stabilization of HIF1, Sdhb-deﬁcient cells were
shown to have signiﬁcantly inhibited pyruvate oxida-
tion, but pyruvate was still metabolized by the mito-
chondria through carboxylation by pyruvate
carboxylase (PC). Indeed, this was found to be criti-
cal for continued Sdhb-deﬁcient cell proliferation
both in vitro and in vivo70,71 most likely due to the
loss of aspartate synthesis in these cells (Figure 2)—
an amino acid required for a number of key anabolic
pathways including protein and nucleotide synthesis.
Importantly, those cells with wild-type SDH activity
were able to tolerate siRNA-induced PC deﬁciency
and maintain their proliferative capability through
continued synthesis of aspartate through the oxida-
tive TCA cycle. The continued production of succi-
nate by SDH-deﬁcient cells indicates the ability of
their mitochondria to retain some NADH oxidative
activity and therefore continued oxidative ATP pro-
duction. Indeed, it appears that glutamine carbons
may represent the major carbon source for the succi-
nate produced,70,71 suggesting that it is the activity of
αKGDH that delivers signiﬁcant NAD+ reducing
activity in the absence of SDH. However, important
questions remain—one of the most intriguing being
whether cells and tumors bearing loss of function of
SDH through mutations in other subunits show the
same metabolic phenotype. This is key, as SDHB-
mutated tumors are the only SDH-mutated tumors
result in malignant tumors. One of the few studies to
examine the differential effects of deﬁciencies of dif-
ferent SDH subunits suggested that RNAi-mediated
reduction in the expression of SDHB led to increased
mitochondrial ROS production, while this was not
recapitulated by similar reduction of SDHA.72 How-
ever, another study has suggested that SDHB deﬁ-
ciency does not result in detectable induction of ROS
production.73 It therefore remains unclear as to the
basis of the malignancy in SDHB-deﬁcient tumors,
and further research is required.
Fumarate Hydratase
FH, encoding the proximal downstream enzyme to
SDH, is another mitochondrial tumor suppressor
gene, the loss of which leads to hereditary leiomyo-
matosis and renal-cell cancer (HLRCC).46 FH-
deﬁcient leiomyomas (a benign neoplasm) are
highly penetrant, while RCC occurs slightly less
FIGURE 2 | Succinate dehydrogenase (SDH) (a) and fumarate hydratase (FH) (b) mutation-mediated alterations in mitochondrial metabolism.
Metabolic pathways that have been shown to be used in cells or tumors containing these mutations are shown. Pathways that are likely to be
used, but have not yet been shown are marked with ‘?’ Abbreviations: AcCoA, acetyl CoA; ACO2, mitochondrial aconitase; a-KG, α-ketoglutarate;
Asp, aspartate; BR, bilirubin; BV, biliverdin; Cit, citrate; Fum, fumarate; Glc, glucose; Gln, glutamine; Glu, glutamate; GSH, reduced glutathione;
Gly, glycine; Lac, lactate; OAA, oxaloacetate; PC, pyruvate carboxylase; PDH, pyruvate dehydrogenase; PDK1, pyruvate dehydrogenase kinase 1;
Pyr, pyruvate; Suc, succinate.
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frequently.74 However, the RCC that develop are
highly aggressive, leading to the early generation of
distant metastases,74 similar to SDHB-deﬁcient
tumors. Although a single gene, processing at the
mitochondrion allows the protein to be distributed
in both cytosolic and mitochondrial comparts-
ments.75
FH is responsible for the hydration of fumarate
to form malate, which can then either be oxidized by
malate dehydrogenase to form NADH and oxaloace-
tate or oxidatively decarboxylated by malic enzyme
to form pyruvate and NADPH (Figure 1). Deﬁcien-
cies in FH lead to high steady-state concentrations of
fumarate in the cell and surrounding extracellular
space. In parallel to succinate, fumarate has been
shown to competitively inhibit αKG-dependent diox-
ygenase enzymes, resulting in a pseudohypoxic tran-
scriptome through HIFα stabilization76 and a
hypermethylator phenotype.76,77 However, contrary
to initial thoughts, now there is evidence to suggest
that stabilization of HIF is not the driver of tumori-
genesis in FH-deﬁcient tumors, and that a different
candidate transcription factor—the nuclear-related
factor 2 (NRF2) pathway—may instead be
involved.78,79
In addition to the truncation of the TCA cycle
and increase in reductive glutamine metabolism that
occurs as a result of loss of FH function,34 fumarate
is also a product of two other metabolic pathways
(in contrast to succinate): the urea and purine nucleo-
tide cycles as well as tyrosine metabolism. The high
concentrations of fumarate produced in FH-deﬁcient
cells have been shown to result in reversal of part of
the urea cycle, producing argininosuccinate and dis-
rupting arginine metabolism within FH-deﬁcient
cells.80,81 In addition, fumarate has been shown to
react with enzymes and other intracellular metabo-
lites in a process known as succination.82–84 This
posttranslational modiﬁcation has been shown to
inhibit mitochondrial aconitase activity in FH-
deﬁcient cells, resulting in further truncation of the
TCA cycle82 (Figure 2). In addition, succination of
reduced glutathione (GSH) to form succinicGSH has
also been demonstrated, which results in the deple-
tion of the intracellular antioxidant pool and senes-
cence.83 Importantly, this sheds further light on the
mutational hits required for an FH-deﬁcient lesion to
become malignant, and suggests that upregulation of
NRF2-dependent antioxidant pathways, as previ-
ously described, is likely to be important to compen-
sate for the reduced GSH pool. In mice, inactivation
of cell cycle inhibitors, such as p21, has been shown
to be important for tumor development in Fh1−/−
kidneys.83 In addition, it is highly likely that other
exposed thiol groups in mitochondrial-associated
enzymes are potential targets of succination, and
therefore other metabolic perturbations may be pres-
ent in these cells.
A bioinformatic analysis of Fh1-deﬁcient cells
highlighted a mitochondrial metabolic ‘bypass’
required for viability.85 Frezza et al. showed that
Fh1-deﬁcient cells continue to oxidize glutamine
through αKGDH (reducing NAD+ for oxidation by
complex I of the respiratory chain) but direct a pro-
portion of the succinyl CoA produced by the subse-
quent enzymatic step of the TCA cycle, succinyl CoA
ligase, through the heme biosynthetic pathway85
(Figure 2). This pathway, which starts and ﬁnishes in
the mitochondrial matrix, uses four molecules each
of succinyl CoA and glycine to produce heme, so
appears to be a very efﬁcient means of removing the
excess carbon from the cell. However, Frezza
et al. showed that the degradation of heme was also
required, as pharmacological block or knockdown of
heme oxygenase, the ﬁrst enzyme in the degradation
of heme, resulted in loss of cell viability.85 Heme deg-
radation releases iron and CO, producing biliverdin
and then bilirubin. Interestingly, the use of this path-
way may not only be due to a requirement to excrete
excess TCA cycle carbon. It has been noted that both
biliverdin and bilirubin can act as antioxidants, capa-
ble of quenching superoxide—perhaps a useful func-
tion in cells deﬁcient for GSH.86,87 Although the
cellular localization of heme oxygenase is not clear, it
is possible that release of the CO in proximity to the
respiratory chain could have consequences for con-
tinued electron ﬂow and therefore NADH-oxidizing
activity. Importantly, the synthesis of heme also
required considerable glycine (1:1 with succinyl
CoA), which is likely to make cells highly dependent
on the glycine synthetic pathways, controlled by ser-
ine hydroxymethyltransferase (SHMT) 1 and 2. As
this part of the pathway occurs in the mitochondrial
matrix, SHMT2, the matrix isozyme may be key in
FH-deﬁcient cell function.
The bioinformatics screen performed on Fh-
deﬁcient cells also highlighted other enzymes that
may be synthetic lethal with loss of Fh1.85 Of partic-
ular note is the mention of PC, which was later
shown to be synthetic lethal with loss of Sdhb,70,71
glutaminase (Gln), which can be understood through
the cells requirement for this amino acid for mito-
chondrial oxidative activity, and SDH. This last pre-
diction is intriguing, but no further data are yet
available to show whether this is a true synthetic
lethal combination with Fh1 deﬁciency.
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Isocitrate Dehydrogenase
IDH enzymes are members of the β-decarboxylating
dehydrogenase family that catalyze the oxidative
decarboxylation of isocitrate to αKG and CO2.
Mammalian cells express three IDH isoforms (1, 2,
and 3) encoded by ﬁve genes (IDH1, 2, 3A/3B/3G)
in the nuclear genome. IDH1 and IDH2 are reversi-
ble, highly homologous (>70%) homodimeric
NADP+-dependent enzymes. IDH3 is an irreversible
heterotetrameric NAD+-dependent enzyme, both
genetically and structurally unrelated to IDH1 and
IDH2. Interestingly, mutations only in IDH1 and
IDH2 have thus far been linked to cancer. The pres-
ence of recurrent somatic point mutations in
IDH1 was ﬁrst identiﬁed in 12% of all adult glio-
blastoma tumors by high-throughput DNA sequen-
cing.51 Deep sequencing further revealed that
mutated IDH1 and IDH2 occur in a high proportion
(>70%) of low-grade (grade II–III) astrocytomas
and oligodendrogliomas and secondary glioblas-
toma.51,52,88,89 Since these initial reports, mutations
in IDH1 and IDH2 have also been found in other
diverse cancers including 16–17% of patients with
AML,53 20% of patients with angioimmunoblastic
T-cell lymphomas,90 and more rarely in
cholangiocarcinomas,91 breast carcinomas,92 acute
lymphoblastic leukemias,93 prostate cancer,93
osteosarcoma,94 and others.53,91–93,95–97 Interest-
ingly, and unlike IDH mutations in glioma which are
almost entirely in IDH1, AML have been shown to
exhibit an approximately equal frequency of IDH1
and IDH2 mutations.53,54
IDH1-mutated gliomas have all been reported
to have a single-point mutation within the codon for
Arg132. It appears that the removal of the arginine,
rather than the substitution of a speciﬁc residue, is
the critical feature of this mutation, although the
most frequent replacement observed is a histidine res-
idue (R132H).51,52,93,98 Mutations in IDH2 in glio-
mas occur at a much lower frequency (0–6%) than
IDH188 in the paralogous amino acid residue—
R140—but also at R172. These residues are key in
the activity of IDH enzymes: Arg132 and Arg172 in
IDH1 and Arg140 and Arg172 in IDH2 form hydro-
philic hydrogen bonds with the α-carboxyl and
β-carboxyl groups of isocitrate to facilitate isocitrate
binding in the enzyme active site.99,100 Mutations in
these residues decrease binding afﬁnity for isocitrate
and increase binding afﬁnity for NADPH, leading to
the reduction of αKG by NADPH and the release of
the (R) enantiomer of 2-hydroxyglutarate [(R)-
2HG].101 The (R)-2HG produced by the mutant IDH
enzymes accumulates in cells to extremely high
millimolar concentrations, disrupting a number of
cellular functions.100 However, it is only the concen-
tration and not the production of (R)-2HG which is
nonphysiological in IDH-mutated tumors, as it is
also produced as a minor product by αKG reductase
enzymes and is oxidized back to αKG by 2HG dehy-
drogenases.102 Interestingly, cells expressing mutant
IDH1 produce less (R)-2HG than those with IDH2
mutations.103 Moreover, (R)-2HG expression by
mutant IDH1 is enhanced by the co-expression of
wild-type IDH1, leading to the formation of hetero-
dimers.100,103 Loss of the wild-type IDH1 expression
results in a dramatic decrease in (R)-2HG
production,104 suggesting either that the presence of
wild-type IDH1 increases the enzymatic activity of
mutant IDH1 toward αKG or that a cycling activity
(redox neutral) permits a higher production of (R)-
2HG with a more stable cell phenotype.
Owing to the structural similarity of (R)-2HG
to αKG, the effect of IDH mutations on members of
the αKG-dependent dioxygenase family of enzymes
has also been studied. Much like SDH- and FH-
mutated tumors, IDH-mutated cells and tumors have
been shown to exhibit a hypermethylator phenotype
through the inhibition of the ten-eleven translocation
(TET) family of DNA demethylases and members of
the Jumonji C-domain histone demethylases through
the competitive inhibition of αKG binding by (R)-
2HG.105–109 However, unlike SDH and FH muta-
tions, the effect of (R)-2HG on PHD activity has
been the subject of some controversy. Although an
initial report suggested that the PHD enzymes were
inhibited by (R)-2HG production resulting in
increased HIF1α protein,110 the evidence that IDH1
mutant cells and tumors actively suppress HIFα stabi-
lization through activation of the PHDs is now more
compelling. The precise means by which (R)-2HG
results in increased PHD enzyme activity, however, is
still not clear. It has been suggested to be through
direct use of only the (R) enantiomer by the PHDs as
a substrate109,111 or through nonenzymatic oxidation
of 2HG into αKG, therefore acting as a source of the
normal substrate.112 Consistent with either mechan-
ism, IDH mutant cells display decreased HIF activa-
tion compared with their wild-type counterparts.109
Mutations in IDH1 and IDH2, in both glioma and
AML, occur early in tumor development and are
thought to be mutually exclusive,52,113 suggesting
that either isoform is sufﬁcient to confer a predisposi-
tion to or permit transformation when mutated. The
IDH1 and IDH2 isozymes differ only in their locali-
zation, yet although they are equally prevalent in
patients with IDH-mutated AML, gliomas with these
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mutations are almost always IDH1-mutated. This
discrepancy has not yet been explored fully, but it is
possible that the environment in which each disease
develops (such as the extent and severity of hypoxia)
and/or a lack of suitable mitochondrial metabolic
plasticity may play a role in determining why IDH2
mutations are not observed often in gliomas.
Gliomas are highly hypoxic tumors.114–116 As
outlined above, it has previously been shown that
hypoxic cells may rely more on reductive glutamine
metabolism to produce citrate (and thereby lipids)
than normoxic cells.30 Both IDH1 and 2 have poten-
tial roles in hypoxia-induced reductive
carboxylation,29,31 suggesting that this pathway may
be perturbed in IDH1-mutated gliomas. Given that
the cytosolic pathway has been shown to be impor-
tant in hypoxic reductive carboxylation for
lipogenesis,30,32–34 and that gliomas appear to ‘favor’
IDH1 mutations, there may be a requirement for
IDH2 wild-type activity in hypoxic IDH1 mutant
gliomas. However, a recent paper also showed that
IDH1-mutated cells retained more of their oxidative
TCA cycle metabolism than their wild-type counter-
parts.117 Under hypoxic conditions, where IDH1
wild-type cells increased their dependence on reduc-
tive carboxylation of glutamine, IDH1 mutant cells
increased their use of oxidative decarboxylation,
most likely retaining oxidative ATP generation in
these conditions. This is consistent with the evidence
that (R)-2HG inhibits hypoxia-induced stabilization
of HIF1α,109 and therefore IDH1-mutated cells may
not exhibit the HIF-dependent metabolic response to
hypoxia, including changes in the activity of the PDC
and complex IV. However, continued oxygen use in
hypoxia is likely to create highly challenging condi-
tions in an IDH1-mutated tumor, as it is likely to
further exacerbate the hypoxic microenvironment,
potentially leading to increased areas of necrosis. It is
important to note that IDH1 mutant gliomas demon-
strate improved overall survival compared to their
wild-type counterparts,52 which may well be in some
part due to their apparent inability to modify their
mitochondrial metabolism in response to hypoxia.
Interestingly, IDH2-mutated cells were shown not to
exhibit the same alteration in the hypoxia-mediated
mitochondrial metabolic phenotype.117 These data
may shed more light on the metabolic differences
induced by IDH1 and IDH2 mutations and therefore
their different prevalence in glioma—a highly
hypoxic type of tumor.
FUTURE PERSPECTIVES
It is thought that the ancestors of mitochondria,
perhaps some type of Rhodobacteria, were organ-
isms with a highly plastic metabolism, able to make
ATP both in the presence and absence of oxygen.
Although our mitochondria are removed from their
predecessors by almost 2 billion years, the muta-
tions that we observe in cancer and studies of other
mammals have shown us that they retain many of
these characteristics. It is also important to note that
studies of mitochondrial metabolism are often cen-
tered around only one small aspect of their
metabolism—the TCA cycle—and ignore other
highly signiﬁcant metabolic pathways for which
mitochondria are critical. While classically being
considered the TCA ‘cycle,’ it is becoming increas-
ingly clear through studies on perturbed mitochon-
drial systems that it in fact consists of multiple
interconnecting metabolic pathways that permit
crosstalk between the mitochondrion and the cyto-
sol. It is only through studies on tumors—highly
proliferative cell systems—that we ﬁnd that the cycle
itself is dispensable, where the use of only some spe-
ciﬁc linear portions of the TCA cycle is required to
fulﬁll the anabolic requirements without signiﬁcant
difﬁculty. However, it is in adapting to the trun-
cated nature of the TCA cycle that SDH-, FH-, and
IDH-mutated and hypoxic cells have been shown to
become highly dependent on one or more pathways
for their survival. These metabolic vulnerabilities
therefore represent attractive targets for future ther-
apeutic development.
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